News & Updates

Show Multimedia Only

Shortened brachytherapy course proves its worth in endometrial cancer

20 Feb 2025 by

Short-course vaginal cuff brachytherapy (VCB) is just as efficacious as standard regimens for adjuvant treatment of endometrial cancer, yielding noninferior patient-reported outcomes without compromising disease control while having acceptable toxicity, according to the phase III, unblinded, multicentre SAVE trial.

Shortened brachytherapy course proves its worth in endometrial cancer

20 Feb 2025

Neoadjuvant docetaxel, radiotherapy feasible in high-risk prostate cancer

20 Feb 2025

Neoadjuvant radiation therapy and docetaxel prior to prostatectomy in men with localized high-risk prostate cancer has a modest toxicity profile and results in reasonable long-term outcomes, but pathologic complete response (pCR) is not achieved, results of a phase I/II trial have shown.

Neoadjuvant docetaxel, radiotherapy feasible in high-risk prostate cancer

20 Feb 2025

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

19 Feb 2025

Patients with metastatic renal cell carcinoma (RCC) may gain significantly better survival outcomes with lenvatinib therapy than with other tyrosine kinase inhibitors (TKIs), suggests a study.

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

19 Feb 2025

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

14 Feb 2025

In the first-line treatment of patients with EGFR-mutated locally advanced or metastatic non–small-cell lung cancer (NSCLC), the novel third-generation EGFR tyrosine kinase inhibitor rezivertinib yields superior overall efficacy and progression-free survival (PFS) when compared with gefitinib, with no new safety signals, according to the phase III REZOR trial.

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

14 Feb 2025

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

13 Feb 2025

For patients with resectable esophageal adenocarcinoma, survival outcomes appear to be better with perioperative chemotherapy with FLOT vs preoperative chemoradiotherapy, according to a phase III study.

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

13 Feb 2025

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025 by

When treating patients with locally advanced esophageal squamous cell carcinoma (ESCC) in the neoadjuvant setting, chemoradiotherapy with or without sintilimab results in significantly higher pathological complete response (pCR) rates compared with chemotherapy plus sintilimab, according to preliminary data from the phase III SCIENCE trial from China.

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

Patients with hepatocellular carcinoma (HCC) who are receiving treatment with the combination of atezolizumab plus bevacizumab may be at risk of variceal bleeding, particularly those with a low platelet count, portal vein invasion, history of gastrointestinal bleeding, and varices needing treatment, as shown in a retrospective study.

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

09 Feb 2025 by

Dual immunotherapy with checkpoint inhibitors nivolumab and ipilimumab works better to slow disease progression in patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) when compared with single-agent nivolumab, as shown in the phase III CheckMate 8HW trial.

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

09 Feb 2025

Gabapentin relieves paclitaxel-induced neuropathic pain

06 Feb 2025

The use of gabapentin is effective in reducing neuropathic pain due to paclitaxel chemotherapy, as shown in a study.

Gabapentin relieves paclitaxel-induced neuropathic pain

06 Feb 2025

SG’s first smartphone-based cancer prehab program sees early success

05 Feb 2025 by

A smartphone-based cancer prehabilitation program in Singapore is feasible and safe, with preliminary data showing high acceptability among local users.

SG’s first smartphone-based cancer prehab program sees early success

05 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

Shortened brachytherapy course proves its worth in endometrial cancer

Shortened brachytherapy course proves its worth in endometrial cancer

Neoadjuvant docetaxel, radiotherapy feasible in high-risk prostate cancer

Neoadjuvant docetaxel, radiotherapy feasible in high-risk prostate cancer

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

Gabapentin relieves paclitaxel-induced neuropathic pain

Gabapentin relieves paclitaxel-induced neuropathic pain

SG’s first smartphone-based cancer prehab program sees early success

SG’s first smartphone-based cancer prehab program sees early success